Keyphrases
Taxanes
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Overall Response Rate
100%
Platinum-based Chemotherapy
100%
Clinical Outcomes
100%
Overall Survival
66%
Progression-free Survival
66%
Pemetrexed
50%
G12V
50%
Chemotherapy Regimen
33%
Gemcitabine
33%
KRAS mutation
33%
Treatment Group
16%
Chemotherapy
16%
Most Common Form
16%
Response Rate
16%
Response to Chemotherapy
16%
Adenocarcinoma
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Non-small Cell Lung Cancer Patients
16%
Bevacizumab
16%
Smoking History
16%
In Vitro Data
16%
Stage IV Disease
16%
Hospital Database
16%
Taxane-based Chemotherapy
16%
Best Overall Response
16%
G12D
16%
G12C
16%
INIS
patients
100%
cancer
100%
comparative evaluations
100%
chemotherapy
100%
platinum
100%
lung cells
100%
mutations
50%
hospitals
20%
diseases
10%
data
10%
in vitro
10%
adenocarcinomas
10%
Medicine and Dentistry
Overall Survival
100%
Progression Free Survival
100%
Non Small Cell Lung Cancer
100%
Pemetrexed
75%
Gemcitabine
50%
Chemotherapy
50%
In Vitro
25%
Adenocarcinoma
25%
Bevacizumab
25%
Diseases
25%
Treatment Group
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Non Small Cell Lung Cancer
100%
Taxane
100%
Overall Survival
57%
Progression Free Survival
57%
Pemetrexed
42%
Gemcitabine
28%
Adenocarcinoma
14%
Bevacizumab
14%
Diseases
14%
Treatment Group
14%